Talcum Powder Cancer Lawsuit

Talcum Powder Lawsuits Dampen Investor Outlook

Although Sales Are Up, Shares Down for J&J Because of Talcum Powder Lawsuits

Wednesday, August 14, 2019 - Investors are on the fence when it comes to a long-term forecast for Johnson & Johnson. Historically a safe investment choice, stockholders are divided for two main reasons: On the one hand, J&J is currently facing major litigation, including more than 15,000 talcum powder lawsuits and national claims for lung problems from talcum powder, a federal investigation, and lawsuits in most states related to the company's role in the opioid crisis. On the other hand, despite all the bad press, the company's second quarter earnings soared in 2019.

With markets generally in decline in the United States as the China trade wars take their toll, investors are seeking to consolidate around safe choices. Historically, J&J would have been one such company: The largest pharmaceutical company in the world, J&J has been both a trusted household name for generations and generally regarded as a blue-chip stock.

While Johnson's Baby Powder cannot compete in revenue with the likes of top-selling prescription drugs, the staple product serves as an emblem of the trust American families place in the J&J brand. The onset of talcum powder lawsuits has rattled the company's reputation, which is a significant factor in investors' choices.

Filed by women who allege their cancer came about as a result of using talcum powder for feminine hygiene, a growing number of talc cancer claims led Reuters to complete an in-depth investigation of the company's talc-based body products over the past four decades. Americans were shocked to see a paper trail of deceit that has exposed millions of women to a heightened risk of deadly ovarian cancer. Several plaintiff won major cases against J&J prior to the Reuters article, but the piece has served to bring public attention to the matter and the number of national talcum powder lawsuits have swelled.

The evidence brought forward by ovarian cancer claims and made public by Reuters indicates the company has relied on a raw talc source that tested positive for asbestos content at many intervals over the decades. A growing number of individuals are now filing claims for mesothelioma from asbestos in talcum powder.

Federal investigators with the U.S. Department of Justice announced they were undertaking an investigation of J&J's handling of talc testing over the decades. This announcement came after the Reuter's piece and no doubt has increased the concern among investors about the stability of J&J's stock.

The company's role in the opioid crisis is another area of vulnerability for the pharmaceutical giant. Most states' attorneys general have filed suits against J&J, saying the company intentionally overproduced opioid drugs and engaged in dishonest and sometimes illegal marketing practices, incentivizing doctors for prescribing the highly addictive drugs.

Amid all this clamor, J&J announced Q2-2019 earnings of $5.61 billion, up 42% from the same period last year. The same day, the company's shares declined 1%, even as J&J boosted its sales forecast for the rest of the year. Only time - and the outcome of prominent lawsuits against the company - will tell J&J's fate in an unruly market.

Information provided by TalcumPowderCancerLawsuit.com, a website devoted to providing news about talcum powder ovarian cancer lawsuits, as well as medical research and findings.

More Recent Talcum Powder Ovarian Cancer Lawsuit News:

View all Talcum Powder Cancer Lawsuit News

No-Cost, No-Obligation Baby Powder Lawsuit Case Review for Persons or Families of Persons Who Developed Ovarian Cancer After a History of Perineal Baby Powder Use

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.